United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support

The National Cancer Institute conducted the clinical trials of Unituxin for treatment of pediatric high-risk neuroblastoma and teamed with United for manufacturing and commercialization.